<p>市場對 <strong>Viking Therapeutics</strong>（VKTX 1.73%）的抗肥胖藥物 VK2735 口服制劑的二期試驗的頂線結果反應平平。這種失望讓人覺得該股票缺乏任何近期的催化劑——VK2735 的皮下（注射）形式的三期結果可能要到 2027 年才能公佈——而對該股票的興奮主要集中在口服制劑上。</p>
<p>然而，這種反應可能過於倉促，投資者仍然有時間買入這隻醫療股。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<h2>Viking Therapeutics 的二期 Venture 試驗出了什麼問題？</h2>
<p>二期 Venture 口服給藥試驗顯示出令人印象深刻的療效。然而，投資者對安全性和耐受性數據感到失望，特別是由於不良事件導致的 20% 的停藥率。這在這裏是一個敏感問題，尤其是 <strong>輝瑞</strong> 在同一類別中也因耐受性數據令人失望而停止了口服減肥藥的開發。</p>
<h2>Viking Therapeutics 的下一步在哪裏？</h2>
<p>Venture 試驗中由於不良反應導致的停藥率高於 <strong>禮來</strong> 和 <strong>諾和諾德</strong> 的口服減肥藥三期試驗中的治療組。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>藥物</th>
<th>試驗</th>
<th>由於不良反應導致的停藥率（治療組）</th>
<th>由於不良反應導致的停藥率（安慰劑）</th>
<th>體重減輕</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735（口服）</td>
<td>Venture（二期）</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>諾和諾德</td>
<td>semaglutide（口服）</td>
<td>Oasis-1（三期）</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>禮來</td>
<td>orforglipron</td>
<td>Attain-1（三期）</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
<p>數據來源：Viking Therapeutics，禮來，心血管教育醫師學院。* 在最高劑量下</p>
<p>然而，一家大型製藥公司可能會對收購 Viking 或與其合作開發 VK2735 的口服形式感興趣，並幫助其通過三期測試，或者在優化劑量後將其推進三期。或者，它可以作為已經通過治療減重的患者的維持治療。</p>
<p>Viking 可能擁有比市場認為的更多選擇。</p>

Viking治療

<p>Viking Therapeutics（VKTX）針對其抗肥胖藥物 VK2735 的第二階段試驗結果令投資者失望，特別是由於不良事件導致的 20% 停藥率。儘管存在擔憂，分析師認為仍可能存在投資機會，因為大型製藥公司可能會收購或與 Viking 合作，以推動 VK2735 進行進一步測試。市場的反應可能過於倉促，因為 Viking 的潛力可能超過目前的認知</p>

<p>The market was less than impressed with the top-line results from <strong>Viking Therapeutics</strong>' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily centered on the oral formulation.</p>
<div class="lb-trans"><p>市場對 <strong>Viking Therapeutics</strong>（VKTX 1.73%）的抗肥胖藥物 VK2735 口服制劑的二期試驗的頂線結果反應平平。這種失望讓人覺得該股票缺乏任何近期的催化劑——VK2735 的皮下（注射）形式的三期結果可能要到 2027 年才能公佈——而對該股票的興奮主要集中在口服制劑上。</p>
</div><p>However, that reaction may prove too hasty, and there's still time to buy into the healthcare stock.</p>
<div class="lb-trans"><p>然而，這種反應可能過於倉促，投資者仍然有時間買入這隻醫療股。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F831787%2Fgirl-investing.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>What went wrong with Viking Therapeutics' phase 2 Venture trial?</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的二期 Venture 試驗出了什麼問題？</h2>
</div><p>The phase 2 Venture oral dosing trial demonstrated impressive efficacy. However, investors were left disappointed by the safety and tolerability data, particularly the 20% rate of discontinuation due to adverse events. This is a sensitive issue here, particularly as <strong>Pfizer</strong> discontinued development of an oral weight loss drug in the same class that also had disappointing tolerability data in a trial.</p>
<div class="lb-trans"><p>二期 Venture 口服給藥試驗顯示出令人印象深刻的療效。然而，投資者對安全性和耐受性數據感到失望，特別是由於不良事件導致的 20% 的停藥率。這在這裏是一個敏感問題，尤其是 <strong>輝瑞</strong> 在同一類別中也因耐受性數據令人失望而停止了口服減肥藥的開發。</p>
</div><h2>Where next for Viking Therapeutics?</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的下一步在哪裏？</h2>
</div><p>Discontinuation rates due to adverse effects in the Venture trial were higher than those in treatment groups in phase 3 trials of oral weight loss drugs by <strong>Eli Lilly</strong> and <strong>Novo Nordisk.</strong></p>
<div class="lb-trans"><p>Venture 試驗中由於不良反應導致的停藥率高於 <strong>禮來</strong> 和 <strong>諾和諾德</strong> 的口服減肥藥三期試驗中的治療組。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Drug</th>
<th>Trial</th>
<th>Discontinuation Rate Due to Adverse Effects (Treated)</th>
<th>Discontinuation Rate Due to Adverse Effects (Placebo)</th>
<th>Body Weight Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735 (oral)</td>
<td>Venture (phase 2)</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>semaglutide (oral)</td>
<td>Oasis-1 (phase 3)</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>orforglipron</td>
<td>Attain-1 (phase 3)</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>藥物</th>
<th>試驗</th>
<th>由於不良反應導致的停藥率（治療組）</th>
<th>由於不良反應導致的停藥率（安慰劑）</th>
<th>體重減輕</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735（口服）</td>
<td>Venture（二期）</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>諾和諾德</td>
<td>semaglutide（口服）</td>
<td>Oasis-1（三期）</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>禮來</td>
<td>orforglipron</td>
<td>Attain-1（三期）</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
</div><p>Data sources: Viking Therapeutics, Eli Lilly, Physicians Academy for Cardiovascular Education. *At highest dosage</p>
<div class="lb-trans"><p>數據來源：Viking Therapeutics，禮來，心血管教育醫師學院。* 在最高劑量下</p>
</div><p>However, a larger pharmaceutical company may be interested in acquiring Viking or partnering with it to develop VK2735 in oral form and help it through phase 3 testing, or, alternatively, take it to phase 3 after optimizing the dosage. Or, it could be used as a maintenance therapy for patients who have already lost weight through treatment.</p>
<div class="lb-trans"><p>然而，一家大型製藥公司可能會對收購 Viking 或與其合作開發 VK2735 的口服形式感興趣，並幫助其通過三期測試，或者在優化劑量後將其推進三期。或者，它可以作為已經通過治療減重的患者的維持治療。</p>
</div><p>Viking may have more options than the market thinks.</p>
<div class="lb-trans"><p>Viking 可能擁有比市場認為的更多選擇。</p>
</div>

覺得現在買入這隻領先的生物科技股票已經太遲了嗎？以下是為什麼仍然有機會的原因